A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.

Is CagriSema FDA approved?

No, CagriSema is not FDA approved. Current status: NDA Submitted - Expected approval late 2026/early 2027

What are the side effects of CagriSema?

Reported side effects of CagriSema include: Nausea, Vomiting, Diarrhea, Constipation, GI events (72-80% vs 34-40% placebo), Higher GI effects than semaglutide alone, Investigational - not yet approved.

What is the typical dosing for CagriSema?

Doses from clinical trials. Common doses observed in research: Semaglutide 2.4mg + Cagrilintide 2.4mg weekly. Duration: Long-term use expected. Administration: Subcutaneous injection weekly.

Weight Loss

CagriSema

Also known as: Semaglutide + Cagrilintide

Clinical Trials

Popular For

Maximum weight loss, combination therapy, obesity

Key Facts: CagriSema

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: NDA Submitted - Expected approval late 2026/early 2027
Administration: Subcutaneous injection weekly
Typical Dose: Limited community data available
Frequency: See research protocols
Evidence Level: Human Trials
Duration: Long-term use expected

Also Known As

Semaglutide + Cagrilintide

Mechanism of Action

Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1.

Research Summary

Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment.

Clinical Status:NDA Submitted - Expected approval late 2026/early 2027

Trial Progress:Preclinical

Pre

III

FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses from clinical trials

Doses from Studies

Semaglutide 2.4mg + Cagrilintide 2.4mg weekly

Clinical Trial Data - Phase 3 Clinical Trials ↗

Duration

Long-term use expected

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea
●Vomiting
●Diarrhea
●Constipation
●GI events (72-80% vs 34-40% placebo)
●Higher GI effects than semaglutide alone
●Investigational - not yet approved

References

Related Peptides

Peptides commonly compared with CagriSema or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Orforglipron

Clinical Trials

An oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

How to Use CagriSema CagriSema Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on CagriSema research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides